查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1572298

BETA 地中海型貧血測試市場：按測試類型、最終用戶、技術分類 - 2025-2030 年全球預測

Beta Thalassemia Testing Market by Test Type (Carrier Screening, Diagnostic Testing, Newborn Screening), End User (Diagnostic Laboratories, Hospitals, Research Institutes), Technology - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年BETA地中海貧血檢測市值為4.4683億美元，預計到2024年將達到4.7847億美元，複合年成長率為8.37%，到2030年將達到7.8435億美元。

BETA-地中海型貧血檢測是遺傳和產前檢測市場的重要組成部分，因為它是一種遺傳性疾病。這包括診斷BETA地中海貧血的基因篩檢，這是一種以血紅蛋白產生減少為特徵的血液疾病。這項測試至關重要，特別是在該疾病高發生率中，例如地中海、中東和東南亞地區，因為它有助於早期診斷和更好地管理疾病。 BETA地中海型貧血檢測的應用範圍包括潛在基因攜帶者的產前檢測、新生兒篩檢以及有症狀個體的明確診斷。最終用途主要是醫院、診斷實驗室和專科診所。

主要市場統計
基準年[2023] 44683萬美元
預測年份 [2024] 47847萬美元
預測年份 [2030] 7.8435 億美元
複合年成長率（%） 8.37%

BETA地中海貧血檢測市場受到成長要素的影響，例如對遺傳疾病認知的提高、次世代定序儀等基因檢測技術的進步以及對促進遺傳疾病篩檢的醫療保健政策的支持。此外，持續的研發工作和策略聯盟以開發更準確、更快速和更具成本效益的測試解決方案也帶來了巨大的機會。例如，利用 CRISPR-Cas9 技術可以提高測試能力，並為有前景的業務擴展領域提供業務洞察。然而，新興國家面臨先進診斷測試的有限性和基因測試通訊協定的嚴格監管等挑戰，影響了整體市場的成長潛力。

透過將人工智慧整合到自動化和資料分析中，在提高檢測精度和降低成本方面存在大量創新機會。與研究機構合作開發綜合基因組也可能增強市場地位。產業參與者應注重地理擴張，尤其是地中海貧血負擔較高的開拓農村地區。市場競爭格局溫和，主要受到技術進步和醫療保健支出成長的推動。能夠在確保合規性和擴大測試範圍的同時進行創新的公司將能夠利用該行業的信譽和成長潛力。

市場動態：揭示快速發展的BETA地中海貧血測試市場的關鍵市場洞察

供需的動態交互作用正在改變BETA地中海貧血檢測市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球BETA-地中海貧血的盛行率不斷上升，增加了對專門檢測方法的需求。
    • 提高人們對BETA-地中海貧血的早期發現和管理的認知並加強政府的努力
    • 擴大發展中地區的醫療基礎設施，以提供BETA地中海貧血檢測
  • 市場限制因素
    • 與先進診斷技術相關的先進測試技術高成本
  • 市場機會
    • 開發一種具有成本效益的檢測方法，使BETA-地中海貧血篩檢廣泛應用
    • 提高公眾意識和政府努力促進BETA地中海貧血檢測和管理
    • 醫療保健提供者和生物技術公司之間的合作推進了BETA地中海貧血檢測
  • 市場挑戰
    • 在農村和人口稀少地區，使用專門醫療設施進行 BETA 地中海貧血檢測的機會有限。

波特五力：駕馭BETA地中海貧血檢測市場的策略工具

波特五力是了解BETA地中海貧血測試市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解BETA地中海貧血檢測市場的外部影響

外部宏觀環境因素在塑造BETA地中海貧血測試市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解BETA地中海貧血檢測市場的競爭狀況

對BETA地中海貧血測試市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 Beta 地中海貧血測試市場供應商的績效評估

FPNV 定位矩陣是評估 Beta 地中海貧血測試市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪BETA地中海貧血檢測市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，BETA 地中海貧血測試市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • BETA-地中海型貧血的盛行率在全球範圍內不斷增加，增加了對專門檢測方法的需求。
      • 提高人們對BETA地中海貧血的早期發現和管理的認知並加強政府的努力
      • 擴大開發中地區的醫療基礎設施允許進行BETA地中海貧血檢測
    • 抑制因素
      • 與先進診斷技術相關的先進測試技術高成本
    • 機會
      • 開發具有成本效益的檢測方法，以實現BETA-地中海貧血篩檢的廣泛應用
      • 政府努力提高公眾意識並促進BETA地中海貧血檢測和管理
      • 醫療保健提供者和生物技術公司之間的合作加速了BETA地中海貧血檢測的進展
    • 任務
      • 在無法獲得專門醫療保健設施的農村和發展中地區進行BETA地中海貧血檢測
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章 按測試類型分類的BETA地中海貧血測試市場

  • 職業篩檢
  • 診斷測試
    • 基因檢測
    • 驗血
  • 新生兒篩檢
  • 產前檢測
    • 侵入性產前檢測
    • 非侵入性產前檢測（NIPT）

第 7 章 BETA 地中海型貧血測試市場：依最終用戶分類

  • 診斷實驗室
  • 醫院
  • 調查機構
  • 專科診所

第 8 章 BETA 地中海型貧血檢測市場：依技術分類

  • 微陣列技術
  • 次世代定序（NGS）
  • PCR（聚合酵素鏈鎖反應）

第9章 美洲BETA地中海貧血檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區BETA地中海貧血檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲BETA地中海貧血檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-9A6A6F297442

The Beta Thalassemia Testing Market was valued at USD 446.83 million in 2023, expected to reach USD 478.47 million in 2024, and is projected to grow at a CAGR of 8.37%, to USD 784.35 million by 2030.

Beta Thalassemia testing is a critical segment within the genetic and prenatal testing market due to the hereditary nature of the disorder. It involves genetic screening to diagnose beta thalassemia, a blood disorder characterized by reduced hemoglobin production. This testing is essential in populations with a high prevalence of the disease, particularly in Mediterranean, Middle Eastern, and Southeast Asian regions, as it aids early diagnosis and better management of the disorder. Applications of beta thalassemia testing span prenatal testing for potential gene carriers, newborn screenings, and confirmatory diagnostics for symptomatic individuals. End-use scope majorly involves hospitals, diagnostic laboratories, and specialized clinics.

KEY MARKET STATISTICS
Base Year [2023] USD 446.83 million
Estimated Year [2024] USD 478.47 million
Forecast Year [2030] USD 784.35 million
CAGR (%) 8.37%

The market for beta thalassemia testing is influenced by growth factors such as increased awareness regarding genetic diseases, advancements in genetic testing technologies like next-gen sequencing, and supportive healthcare policies promoting genetic disorder screening. Moreover, ongoing research and development activities and strategic collaborations for developing more precise, faster, and cost-effective testing solutions present significant opportunities. For instance, leveraging CRISPR-Cas9 technology could enhance testing capabilities, offering business insights into promising areas for expansion. However, the market faces challenges like limited accessibility to advanced diagnostic tests in emerging economies and regulatory stringencies concerning genetic testing protocols, impacting overall growth potential.

Innovation opportunities abound in improving testing accuracy and reducing costs through automation and integration of AI in data analysis. Collaborations and partnerships with research institutions for developing comprehensive genetic panels can also enhance market standing. Industry players should focus on expanding geographically, especially in untapped rural regions with a high thalassemia burden. The beta thalassemia testing market presents a moderately competitive landscape, primarily driven by technological advancements and increasing healthcare expenditure. Companies that can innovate while ensuring compliance and expanding access to testing will likely capitalize on the sector's credibility and growth potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Beta Thalassemia Testing Market

The Beta Thalassemia Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of beta thalassemia worldwide driving demand for specialized testing methods
    • Rising awareness and government initiatives for early detection and management of beta thalassemia
    • Expansion of healthcare infrastructure in developing regions providing access to beta thalassemia testing
  • Market Restraints
    • High costs of advanced testing technologies associated with advanced diagnostic technologies
  • Market Opportunities
    • Development of cost-effective testing methods enabling widespread adoption of beta thalassemia screening
    • Rising public awareness and government initiatives promoting beta thalassemia testing and management
    • Collaborations between healthcare providers and biotech firms facilitating beta thalassemia test advancements
  • Market Challenges
    • Limited access to specialized healthcare facilities in rural and underdeveloped regions for beta thalassemia testing

Porter's Five Forces: A Strategic Tool for Navigating the Beta Thalassemia Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Beta Thalassemia Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Beta Thalassemia Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Beta Thalassemia Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Beta Thalassemia Testing Market

A detailed market share analysis in the Beta Thalassemia Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Beta Thalassemia Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Beta Thalassemia Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Beta Thalassemia Testing Market

A strategic analysis of the Beta Thalassemia Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Beta Thalassemia Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, Asuragen, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., bioMerieux SA, Cepheid, F. Hoffmann-La Roche Ltd., GenMark Diagnostics, Illumina, Inc., Immucor, Inc., Luminex Corporation, PerkinElmer, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Trinity Biotech.

Market Segmentation & Coverage

This research report categorizes the Beta Thalassemia Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Carrier Screening, Diagnostic Testing, Newborn Screening, and Prenatal Testing. The Diagnostic Testing is further studied across Genetic Testing and Hematological Testing. The Prenatal Testing is further studied across Invasive Prenatal Testing and Non-Invasive Prenatal Testing (NIPT).
  • Based on End User, market is studied across Diagnostic Laboratories, Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Technology, market is studied across Microarray Technology, Next-Generation Sequencing (NGS), and PCR (Polymerase Chain Reaction).
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of beta thalassemia worldwide driving demand for specialized testing methods
      • 5.1.1.2. Rising awareness and government initiatives for early detection and management of beta thalassemia
      • 5.1.1.3. Expansion of healthcare infrastructure in developing regions providing access to beta thalassemia testing
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of advanced testing technologies associated with advanced diagnostic technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of cost-effective testing methods enabling widespread adoption of beta thalassemia screening
      • 5.1.3.2. Rising public awareness and government initiatives promoting beta thalassemia testing and management
      • 5.1.3.3. Collaborations between healthcare providers and biotech firms facilitating beta thalassemia test advancements
    • 5.1.4. Challenges
      • 5.1.4.1. Limited access to specialized healthcare facilities in rural and underdeveloped regions for beta thalassemia testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Beta Thalassemia Testing Market, by Test Type

  • 6.1. Introduction
  • 6.2. Carrier Screening
  • 6.3. Diagnostic Testing
    • 6.3.1. Genetic Testing
    • 6.3.2. Hematological Testing
  • 6.4. Newborn Screening
  • 6.5. Prenatal Testing
    • 6.5.1. Invasive Prenatal Testing
    • 6.5.2. Non-Invasive Prenatal Testing (NIPT)

7. Beta Thalassemia Testing Market, by End User

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Hospitals
  • 7.4. Research Institutes
  • 7.5. Specialty Clinics

8. Beta Thalassemia Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. Microarray Technology
  • 8.3. Next-Generation Sequencing (NGS)
  • 8.4. PCR (Polymerase Chain Reaction)

9. Americas Beta Thalassemia Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Beta Thalassemia Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Beta Thalassemia Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. ARUP Laboratories
  • 4. Asuragen, Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Biocept, Inc.
  • 7. bioMerieux SA
  • 8. Cepheid
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. GenMark Diagnostics
  • 11. Illumina, Inc.
  • 12. Immucor, Inc.
  • 13. Luminex Corporation
  • 14. PerkinElmer, Inc.
  • 15. QIAGEN N.V.
  • 16. Quest Diagnostics Incorporated
  • 17. Siemens Healthineers AG
  • 18. Sysmex Corporation
  • 19. Thermo Fisher Scientific Inc.
  • 20. Trinity Biotech

LIST OF FIGURES

  • FIGURE 1. BETA THALASSEMIA TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. BETA THALASSEMIA TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BETA THALASSEMIA TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BETA THALASSEMIA TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BETA THALASSEMIA TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BETA THALASSEMIA TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HEMATOLOGICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING (NIPT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. BETA THALASSEMIA TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. BETA THALASSEMIA TESTING MARKET, FPNV POSITIONING MATRIX, 2023